North America Antibody Drug Conjugates Market

North America Antibody Drug Conjugates Market Size, Share & Industry Trends Analysis Report By Application (Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others), By Technology, By Country and Growth Forecast, 2022 - 2028

Report Id: KBV-9016 Publication Date: May-2022 Number of Pages: 84
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The North America Antibody Drug Conjugates Market would witness market growth of 13.7% CAGR during the forecast period (2022-2028).

ADCs are anticancer medications that are one of the quickest treatments for cancer patients, with the ability to use the selectivity of monoclonal antibodies against targeted antigens to release potentially lethal chemicals with enhanced activity and lower toxicity than chemotherapies. For cancer treatment, ADCs use antibodies as a vehicle to provide high-potency cytotoxic drug molecules to particular tumor-related antigens. The approval of ten ADCs, including Adcetris and Kadcyla, which are specific for Cd30 and HER2 antigen sites, respectively, demonstrates recent breakthroughs in ADC technology.

The overall share of people aged 65 and up will reach close to 16 percent by 2050. For example, according to the World Health Organization (WHO), by 2050, 80 percent of the world's elderly would be living in OECD countries. The impact of an ageing population on health care systems will be significant.

The antibody-drug conjugate industry in the region is extremely competitive, due to a large number of market players. The rising multiplication of technologically revolutionary technologies in nations such as Canada, the United States, and Mexico, this region is predicted to rapidly control the market. In terms of clinical data, North America is a relatively developed region, and the use of ADCs is considered and accounts for the vast bulk of the established market. Pfizer, for example, acquired Amplyx Pharmaceuticals in April 2021 to create antibody-drug conjugates and other cancer medicines.

For instance, according to the American Cancer Society, an estimated 2, 87,850 new cases of invasive breast cancer would be identified in women in the United States year 2020. In addition, 48,530 cases of in situ breast cancer in women have been investigated, with the number of malignant breast cases predicted to rise in the coming years. Over the forecast period, the growing cases of breast cancer and the existence of good healthcare infrastructure in the region are supposed to drive the antibody drug conjugates market's overall growth.

The US market dominated the North America Antibody Drug Conjugates Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,845 Million by 2028. The Canada market is experiencing a CAGR of 16.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 15.2% during (2022 - 2028).

Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.

Scope of the Study

Market Segments Covered in the Report:

By Application

  • Breast Cancer
  • Blood Cancer
  • Urothelial Cancer & Bladder Cancer
  • Others

By Technology

  • Cleavable Linker
  • Non-Cleavable Linker
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Key Market Players

List of Companies Profiled in the Report:

  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Gilead Sciences, Inc.
  • Seagen, Inc.
  • ADC Therapeutics SA
  • Daiichi Sankyo Company, Limited
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo